

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-68. (canceled)

69. (currently amended): A method of delivering a drug substance into an intradermal compartment of a human subject's skin, said method comprising administering the drug substance through at least one small gauge hollow needle having an outlet with an exposed height between 0 and 1 mm, said outlet being inserted into the skin to a depth of between 0.3 mm and 2 mm, such that delivery of the drug substance occurs at a depth between 0.3 mm and 2 mm, wherein a dosage of the drug substance for achieving a systemic bioavailability of the drug substance is reduced by at least 10% compared to the dose required to achieve the systemic bioavailability when the drug substance is delivered to a subcutaneous compartment of the human subject's skin, wherein the systemic bioavailability of the drug is measured by a determination of its AUC.

70. (previously presented): The method of claim 69, wherein the systemic bioavailability results in a therapeutic or diagnostic effect.

71. (currently amended): The method of claim 69 wherein the administering comprises inserting the needle so that the drug substance is deposited at a depth of at least about 0.3 mm below the surface of the human subject's skin to no more than about 2 mm below the surface of the human subject's skin.

72. (currently amended): The method of claim 69 wherein the administering comprises inserting the needle into the skin so that the drug substance is deposited at a depth of at least about 0.3 mm and no more than about 2 mm.

73. (currently amended): The method of claim 69 wherein the drug substance is administered over a time period of not more than ten minutes.

74. (currently amended): The method of claim 69 wherein the drug substance is administered at a rate between 1 nL/min and 200 mL/ min.
75. (previously presented): The method of claim 69 wherein the needle(s) are inserted substantially perpendicularly to the skin.
76. (canceled)
77. (previously presented): The method of claim 69 wherein the dosage is reduced by at least 20%.
78. (previously presented): The method of claim 69 wherein the dosage is reduced by at least 30%.
79. (currently amended): The method of claim 69 wherein the drug substance is a peptide, protein or nucleic acid.
80. (canceled)
81. (currently amended): The method of claim 69 wherein the drug substance is hydrophobic.
82. (currently amended): The method of claim 69 wherein the drug substance is hydrophilic.
83. (currently amended): The method of claim 69 wherein the drug substance is a hormone.
84. (currently amended): The method of claim 69 wherein the drug substance is selected from the group consisting of insulin, granulocyte stimulating factor and PTH.

85. (currently amended): A method of delivering a drug substance into an intradermal compartment of a human subject's skin, said method comprising injecting or infusing the drug substance intradermally through one or more microneedles having a length sufficient to penetrate the intradermal compartment and an outlet at a depth within the intradermal compartment wherein a dosage of the drug substance for achieving a systemic bioavailability of the drug substance is reduced by at least 10% compared to the dose required to achieve the systemic bioavailability when the drug substance is delivered to a subcutaneous compartment of the human subject's skin, wherein the systemic bioavailability of the drug is measured by a determination of its AUC.

86. (previously presented): The method of claim 85 wherein the length of the microneedle(s) is from about 0.5 mm to about 1.7 mm.

87. (previously presented): The method of claim 85 wherein the microneedle is a 30 to 34 gauge needle.

88. (previously presented): The method of claim 85 wherein the microneedle has an outlet with an exposed height between 0 and 1 mm.

89. (previously presented): The method of claim 85 wherein the microneedle is configured in a delivery device which positions the microneedle perpendicular to skin surface.

90. (previously presented): The method of claim 85 wherein the microneedle is contained in an array of microneedles.

91. (previously presented): The method of claim 90 wherein the array comprises 3 microneedles.

92. (previously presented): The method of claim 90 wherein the array comprises 6 microneedles.

93. (currently amended): The method of claim 85 wherein the drug substance is administered over a time period of not more than ten minutes.
94. (currently amended): The method of claim 85 wherein the drug substance is administered at a rate between 1 nL/min and 200 mL/min.
95. (previously presented): The method of claim 85 wherein the microneedle(s) are inserted substantially perpendicularly to the skin.
96. (canceled)
97. (previously presented): The method of claim 85 wherein the dosage is reduced by at least 20%.
98. (previously presented): The method of claim 85 wherein the dosage is reduced by at least 30%.
99. (currently amended): The method of claim 85 wherein the drug substance is a peptide, protein, or nucleic acid.
100. (currently amended): The method of claim 85 wherein the drug substance is a hormone.
101. (currently amended): The method of claim 85 wherein the drug substance is hydrophobic.
102. (currently amended): The method of claim 85 wherein the drug substance is hydrophilic.
103. (currently amended): The method of claim 85 wherein the drug substance is selected from the group consisting of insulin, granulocyte stimulating factor and PTH.

Appl. No. 10/028,989
Amdt. dated February 26, 2009
Reply to Office Action of November 26, 2008

104. (currently amended): The method of claim 69 or 85 wherein the drug substance is used for the treatment of a symptom of a pathological condition.

105. (currently amended): The method of claim 85, wherein delivery of the drug substance occurs at a depth between 0.3 to 2.0 mm

Claims 106-107 (canceled)